1324010-74-3Relevant academic research and scientific papers
BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS
-
, (2020/10/20)
The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs, e.g., compounds of Formula I (including Formulas IA, IB, IC, ID, IE, IF, and IG), a stereoisomer thereof, or
DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS
-
, (2019/02/13)
The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by lAPs. In particular the present compounds and compositions may be used to treat lAP-mediated ovarian cancer and hepatitis B infection.
Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP
González-Lpez, Marcos,Welsh, Kate,Finlay, Darren,Ardecky, Robert J.,Ganji, Santhi Reddy,Su, Ying,Yuan, Hongbin,Teriete, Peter,MacE, Peter D.,Riedl, Stefan J.,Vuori, Kristiina,Reed, John C.,Cosford, Nicholas D.P.
, p. 4332 - 4336 (2011/08/06)
We report the systematic rational design and synthesis of new monovalent Smac mimetics that bind preferentially to the BIR2 domain of the anti-apoptotic protein XIAP. Characterization of compounds in vitro (including 9i; ML101) led to the determination of key structural requirements for BIR2 binding affinity. Compounds 9h and 9j sensitized TRAIL-resistant breast cancer cells to apoptotic cell death, highlighting the value of these probe compounds as tools to investigate the biology of XIAP.
